In a 2014 mouse elevated-plus-maze study, an ethanolic extract of Convolvulus pluricaulis given orally at 500 mg/kg produced a mean open-arm time of 84.0 ± 12.5 seconds, compared with 23.4 ± 5.3 seconds in untreated controls. Diazepam at 1 mg/kg produced 156.6 ± 32.8 seconds. These results support an anxiolytic-like effect in one animal model, but they do not show that the extract has “54% of diazepam’s potency.” Potency cannot be calculated by directly comparing one behavioural endpoint at dissimilar doses, and the experiment did not establish clinical efficacy in people.
This captures the present state of Shankhpushpi research: a credible preclinical signal and a modern pharmacopoeial identity, but major uncertainty about species, extract composition, mechanism, human dosing, interactions, and effectiveness for diagnosed anxiety disorders.
The Identity Problem: Which Plant Is Shankhpushpi?
The first research question is botanical, not pharmacological. “Shankhpushpi” has been applied to more than one plant in Indian practice and commerce. A comparative pharmacognostic investigation published in 2010 documented four plants traditionally traded or used under the name:
- Convolvulus pluricaulis Choisy (Convolvulaceae)
- Evolvulus alsinoides L. (Convolvulaceae)
- Clitoria ternatea L. (Fabaceae)
- Canscora decussata (Roxb.) Schult. (Gentianaceae)
These names are not interchangeable experimental labels. The 2010 study compared morphology, microscopy, physicochemical constants, and chromatographic fingerprints to support authentication. A paper or product that says only “Shankhpushpi” may therefore be impossible to reproduce reliably.
The Ayurvedic Pharmacopoeia of India, Part I, Volume II, defines Shankhapushpi as the dried whole plant of Convolvulus pluricaulis Choisy. Its monograph describes a prostrate or sub-erect, spreading, hairy perennial herb with a woody rootstock. The same monograph notes that Clitoria ternatea and Evolvulus alsinoides are used as Shankhapushpi in certain parts of India. Thus, the pharmacopoeia supplies a reference identity while also acknowledging regional substitution.
A 2016 study developed an internal-transcribed-spacer multiplex PCR assay to distinguish Convolvulus prostratus—the name used by those authors for the plant also cited as C. pluricaulis—from E. alsinoides. It generated species-specific products of 200 and 596 base pairs and detected 10% admixture. Molecular testing is useful, but trials still need documented sourcing, voucher specimens, and chemical standardization.
Classical and Pharmacopoeial Profile
In the Charaka Samhita tradition, Shankhapushpi is grouped with Mandukaparni, Yashtimadhu, and Guduchi in medhya rasayana practice. “Medhya” concerns intellect, memory, and mental faculties within Ayurveda; it is not automatically a claim to treat generalized anxiety disorder, dementia, or another modern diagnosis.
The official pharmacopoeial monograph gives the following attributes for Convolvulus pluricaulis. These are the API entries and should not be replaced with properties copied from a different regional substitute or later secondary source:
| Ayurvedic category | API description |
|---|---|
| Rasa | Tikta, Katu, Kashaya |
| Guna | Snigdha, Pichchila |
| Virya | Shita |
| Vipaka | Madhura |
| Karma | Tridoshahara, Rasayana, Medhya, Balya, Mohanashaka, Ayushya |
The API lists manasaroga and apasmara among therapeutic uses and gives 3–8 g of powder as the monograph dose. These categories are not exact synonyms for contemporary anxiety disorders or epilepsy and require qualified clinical interpretation.
What the Anxiety Studies Actually Show
The evidence most often cited for anxiety consists mainly of rodent experiments. These studies can identify a behavioural signal and guide mechanism research, but they cannot determine whether an authenticated product is effective, safe, or appropriately dosed for a person with an anxiety disorder.
| Study | Material and design | Verified finding | Main limitation |
|---|---|---|---|
| Nahata and colleagues, 2009 | Rodent experiments using ethyl-acetate fractions of E. alsinoides and C. pluricaulis | Both materials produced anxiolytic-like effects in behavioural tests | Animal data from selected fractions; not a human trial |
| Malik and colleagues, 2011 | Extracts from three commonly used botanical sources of Shankhpushpi | Nootropic, anxiolytic-like, and CNS-depressant activities varied by plant source and dose | Source-dependent results prevent a single conclusion for every “Shankhpushpi” product |
| Siddiqui and colleagues, 2014 | Mice given aqueous, ethanolic, or chloroform extracts of C. pluricaulis at 500 mg/kg | All three extracts increased open-arm time; ethanolic extract reached 84.0 seconds versus 23.4 seconds in controls | Single acute animal experiment with a high extract dose |
| Heba and colleagues, 2017 | Mouse model of ethanol intake and withdrawal | Shankhpushpi reduced withdrawal-associated anxiety-like behaviour and altered cortico-hippocampal GABA findings | A model of alcohol withdrawal, not ordinary clinical anxiety |
Open-arm time is a behavioural proxy, not a direct measure of calmness, receptor occupancy, or therapeutic equivalence. The extract also lacked a quantified marker specification. Because different botanical sources produce different CNS profiles, future trials should report the Latin binomial, plant part, solvent, extraction ratio, voucher specimen, contaminant testing, fingerprint, and marker range.
GABAergic Activity: A Plausible Pathway, Not a Settled Human Mechanism
The 2014 paper proposed possible involvement of the GABA-benzodiazepine system, but it did not measure receptor binding, chloride flux, or human GABA-A activity. Claims of proved benzodiazepine-site agonism or benefit without tolerance go beyond its evidence.
The 2017 ethanol-withdrawal experiment provides more specific preclinical support. In that mouse model, the anti-anxiety-like effect was blocked by a GABA-A antagonist, and chronic administration was associated with increased cortico-hippocampal GABA. This supports GABA-A involvement under the conditions of that experiment. It does not establish GABA-A as the sole mechanism of every preparation or predict the size of an effect in human anxiety.
Reviews report alkaloids, coumarins, flavonoids, and phytosterols in C. pluricaulis, including shankhpushpine, convolamine, scopoletin, kaempferol, and beta-sitosterol. Presence does not establish mechanism, and content varies with identity and extraction. The API gives only the broad constituent entry “alkaloid,” not a clinical standard for anxiety.
Mechanistic caution: A 2022 network-pharmacology paper predicted multiple targets and pathways relevant mainly to dementia research. Computational target mapping is hypothesis-generating. It cannot confirm that a compound reaches the human brain at an active concentration, binds the predicted target in vivo, or improves a clinical outcome.
Cognition and Memory: Promising Preclinical Data, Limited Clinical Proof
The cognition literature remains dominated by laboratory models. Rodent studies report effects after scopolamine- or aluminium-associated impairment. In one aluminium-neurotoxicity model, C. pluricaulis affected muscarinic M1 receptor, choline acetyltransferase, and NGF-TrkA expression. These findings do not establish prevention or treatment of human dementia.
Another rodent study used piracetam as a reference in learning and memory tests. A reference group does not establish clinical equivalence, and animal performance cannot be turned into a prescribing comparison.
Human evidence is modest. A 2015 comparative study enrolled 102 healthy young volunteers and evaluated four 500 mg Shankhapushpi tablets twice daily after food with milk for two months against a programme involving yoga and Satvavajaya Chikitsa. Some memory measures improved, but the herbal intervention was not tested against an inert placebo under a fully blinded design, and the participants did not have anxiety disorders or dementia. The study therefore offers preliminary information about cognitive testing, not proof of treatment for a psychiatric or neurodegenerative condition.
An Alzheimer’s Drug Discovery Foundation evidence review likewise concluded that well-controlled human data are lacking. Comparative trials have not established superior safety or efficacy over prescription drugs.
Dose and Preparation: What Can Be Stated Reliably
Mouse doses should not be converted into self-treatment doses by simple body-surface-area arithmetic. Such calculations do not account for extract ratio, constituent exposure, metabolism, product quality, or indication.
| Preparation or context | Verified amount | How to interpret it |
|---|---|---|
| API whole-plant powder | 3–8 g | Pharmacopoeial monograph dose for the authenticated crude drug; not evidence of efficacy for generalized anxiety disorder |
| Tablet used in the 2015 volunteer study | Four 500 mg tablets twice daily for 60 days | A study-specific regimen in healthy young adults; not a universal clinical dose |
| Commercial syrups, capsules, and extracts | No single evidence-based equivalent dose | Concentration, species, plant part, extraction ratio, sugar content, and marker compounds may differ |
A useful label states the botanical name, plant part, crude-drug equivalent, solvent and ratio, and batch testing. “Shankhpushpi 500 mg” is incomplete when products may contain powder, concentrated extract, or another species.
Safety and Herb–Drug Interactions
Human safety information is insufficient for confident claims about long-term use or combinations with psychiatric and neurological medicines. Traditional use cannot replace adverse-event monitoring and interaction studies.
- Phenytoin: A 1992 report described two patients who lost seizure control while using a Shankhapushpi preparation with phenytoin. Repeated administration in rats reduced phenytoin concentration and anticonvulsant activity. Although botanical authentication was inadequate by current standards, patients should not combine them without the prescribing clinician.
- Benzodiazepines, sedating antihistamines, alcohol, and other CNS depressants: Some extracts show CNS-depressant or sleep-potentiating activity in animals. Additive drowsiness is a reasonable precaution, although human risk is unquantified.
- Antihypertensive treatment: Limited summaries note possible blood-pressure-lowering effects. A person with low blood pressure or prescribed antihypertensives should seek clinical advice and monitoring rather than assuming the combination is harmless.
- SSRIs, SNRIs, and other antidepressants: Computational literature does not establish a clinical serotonin-syndrome interaction. Combination safety is inadequately studied.
- Pregnancy, breastfeeding, children, liver or kidney disease: Adequate controlled safety data are lacking. Unsupervised medicinal use should be avoided in these groups unless an appropriately qualified clinician has assessed the individual situation.
Safety advice: Do not stop or replace prescribed anxiety, seizure, sleep, or blood-pressure treatment with Shankhpushpi. Discuss the exact product with the prescribing healthcare provider and a qualified Ayurvedic practitioner, especially when symptoms are severe or medicines are already used.
Research Gaps That Should Shape the Next Trial
The evidence does not show that Shankhpushpi “works like a benzodiazepine.” It shows that authenticated C. pluricaulis deserves better-designed human research addressing the following gaps.
- Diagnosed anxiety populations: PubMed-indexed literature does not provide an adequately powered, double-blind, placebo-controlled trial of authenticated C. pluricaulis for a defined anxiety disorder.
- Botanical authentication: Trials need a voucher specimen and molecular or validated pharmacognostic confirmation, not only the common name Shankhpushpi.
- Chemical standardization: Extract ratio, solvent, fingerprint, marker range, contaminants, pesticides, microbes, and heavy metals should be reported batch by batch.
- Pharmacokinetics: Human absorption, active metabolites, brain exposure, half-life, and dose proportionality have not been established for a clinically standardized preparation.
- Safety and interactions: Studies should prospectively monitor sedation, cognition, blood pressure, liver and kidney indices, withdrawal effects, and interactions with commonly prescribed medicines.
- Clinically meaningful outcomes: A future trial should use a preregistered primary anxiety scale, functional outcomes, adverse-event reporting, and follow-up after discontinuation rather than relying only on laboratory memory tests or subjective impressions.
Where the Evidence Leaves Us
Shankhpushpi has a genuine Ayurvedic context, an API monograph for Convolvulus pluricaulis, and anxiolytic-like and cognitive signals in animal models. That justifies investigation, not a percentage comparison with diazepam, confirmed GABA-A agonism in people, or replacement of evidence-based anxiety care.
A defensible next step is a preregistered, randomized, double-blind, placebo-controlled study using authenticated, chemically characterized C. pluricaulis, preceded by dose-finding and safety work. Until then, species verification, professional supervision, medication review, and honest uncertainty are more appropriate than promotional certainty.
References
- Openneurologyjournal (openneurologyjournal.com)
- Neuropharmacological Profile of Extracts of Aerial Parts of Convolvulus pluricaulis Choisy in Mice Model (2014), PubMed
- Comparative pharmacognostical investigation on four ethanobotanicals traditionally used as Shankhpushpi in India (2010), PubMed
- Comparative pharmacognostical investigation on four ethanobotanicals traditionally used as Shankhpushpi in India (2010), PubMed Central
- Ayurvedic Pharmacopoeia of India
- Nootropic herbs (Medhya Rasayana) in Ayurveda: An update (2012), PubMed Central
- Internal transcribed spacer guided multiplex PCR for species identification of Convolvulus prostratus and Evolvulus alsinoides (2016), PubMed Central
- Tandfonline (tandfonline.com)
- Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi (2011), PubMed
- Effect of Shankhpushpi on Alcohol Addiction in Mice (2017), PubMed Central
- Frontiersin (frontiersin.org)
- Protective Mechanisms of Nootropic Herb Shankhpushpi (Convolvulus pluricaulis) against Dementia: Network Pharmacology and Computational Approach (2022), PubMed Central
- In vivo investigation of the neuroprotective property of Convolvulus pluricaulis in scopolamine-induced cognitive impairments in Wistar rats (2011), PubMed Central
- Neuroprotective role of Convolvulus pluricaulis on aluminium induced neurotoxicity in rat brain (2009), PubMed
- Nootropic efficacy of Satvavajaya Chikitsa and Ayurvedic drug therapy: A comparative clinical exposition (2015), PubMed
- Alzdiscovery (alzdiscovery.org)
- Analysis of a clinically important interaction between phenytoin and Shankhapushpi, an Ayurvedic preparation (1992), PubMed
Nothing in this article diagnoses or treats a medical condition. Use it as educational information and consult a qualified Ayurvedic practitioner or physician before starting herbs, supplements, detoxes, or therapeutic protocols, especially if pregnant, managing a condition, or taking medication.
The 259% increase in open-arm exploration in the plus maze is a genuinely striking data point. The careful framing that a RCT still hasn’t happened for Shankhpushpi is refreshing. Most herb articles either ignore or inflate preclinical data.
I am a clinical psychologist. The anxiety-nootropic overlap in Shankhpushpi is interesting and matches what I see clinically, that cognitive symptoms and anxiety symptoms often share a common root. A plant that addresses both simultaneously through a different mechanism than benzodiazepines would be valuable.
My integrative medicine doctor explicitly warned me against anxiety given my current medications. The drug interaction issue is real and needs more attention in articles like this.
The GABA-A receptor interaction of the alkaloids described here would put Shankhpushpi in a mechanistic category close to benzodiazepines. Does that raise any concern about tolerance or dependence with long-term use? The article does not address this.
The article highlights that Shankhpushpi can refer to four different plants, which makes reproducing results tricky.
Used Convolvulus pluricaulis based Shankhpushpi ghrita for 6 months for exam anxiety while studying for engineering entrance. The focus improvement was more notable than the anxiety reduction but both were real. Compared to nothing, the change was significant enough that I continued through exams.
As a pharmacology researcher I am frustrated by the lack of clinical trials on this herb. The preclinical profile is genuinely interesting and the traditional use is extensive. The fact that funding mechanisms don’t support patentable natural compounds means good leads like this never get fully developed.
It notes that the ethanolic extract gave mice 84 seconds in the open arm test versus 23 seconds for controls.
My son’s school performance and anxiety improved significantly after starting Shankhpushpi syrup. He is 14. Before I continue this I want to know whether the clinical evidence is comparable for adolescents versus adults and whether there are any developmental concerns.
Research suggests a GABA benzodiazepine pathway but the paper did not measure receptor binding in humans.
The comparison with diazepam at 54 percent of the reference drug’s effect in the preclinical model is remarkable. Most botanical anxiolytics don’t come close to that efficacy range in animal models. Whether that translates to humans is unproven but the mechanism is real.
One practical point is that mouse doses cannot be simply scaled to human amounts using body surface area math.
Some readers might wonder about combining Shankhpushpi with phenytoin given the 1992 case report.
The piece calls for a double blind placebo controlled trial in diagnosed anxiety patients using authenticated material.
A voucher specimen and molecular testing are recommended to fix the botanical confusion.
For Shankhpushpi for Anxiety, consistency seems like the hard part. The main idea is clear even if someone is new to Ayurveda.
For Shankhpushpi for Anxiety, consistency seems like the hard part. This feels more usable than a long list of herbs.
Studies should report the plant part, solvent, extraction ratio, and marker range for each batch.
I appreciate the caution about not equating the animal effect with a percentage of diazePAM’s potency.
It notes that cognitive benefits seen in rodents do not automatically translate to human memory enhancement.
The Ayurvedic pharmacopoeia lists 3 to 8 grams of powder as the traditional dose, but that is not proven for anxiety.
Future work should prospectively track sedation, liver enzymes, and possible interactions with SSRIs.
Until clearer human data appear, species verification and professional supervision remain the safest approach.
great info on combining with Jatamansi. the dosage breakdown is super clear
finally tried combining with Jatamansi after reading this. no miracle cure but genuinely helpful
Not dismissing combining with Jatamansi entirely but it didn’t do much for me. My constitution might be different.
The part about Shankhpushpi syrup vs powder finally cleared up something I’d been confused about for months.
The Shankhpushpi syrup vs powder schedule in section 2 , is that for all three doshas or specifically for Kapha?
Good reminder on Shankhpushpi for Anxiety. I would like to know how long to try it before judging results.
My naturopath recommended Shankhpushpi syrup vs powder and I wanted more background on the classical reasoning. ❤️
Tried 500mg dose timing for 6 weeks, honestly didn’t notice much. Maybe my dosage was off. 🙌
Does anxiety vs depression distinction interact with metformin? Would appreciate a separate post on herb-drug combos.
my ayurvedic doctor told me the same thing about anxiety vs depression distinction last month. glad to see it here
fair enough. the anxiety vs depression distinction evidence really is patchy at best
Is there an age limit for the GABA modulation claim? Asking for my 68-year-old father.
I came for Shankhpushpi for Anxiety and this answered the main question. I would like to know how long to try it before judging results.
great info on Shankhpushpi syrup vs powder. the dosage breakdown is super clear
Good info.
Picked up the anxiety vs depression distinction prep from the section on seasonal variation. Results after 4 weeks: good.
The evidence base for combining with Jatamansi seems thin. Are there actual RCTs or just observational studies?
great info on the GABA modulation claim. the dosage breakdown is super clear
Tried anxiety vs depression distinction for 6 weeks, honestly didn’t notice much. Maybe my dosage was off.
interesting but i disagree with the the GABA modulation claim approach. my experience was the opposite
The evidence base for 500mg dose timing seems thin. Are there actual RCTs or just observational studies?
Sharing this with my mother, she has been struggling with exactly what the combining with Jatamansi section describes.
Have been doing Shankhpushpi syrup vs powder for about 3 months. Saw improvement in month 2, slight plateau now.
My grandmother used to do exactly what you described for 500mg dose timing. Never had a name for it until now.
Is there an age limit for Shankhpushpi syrup vs powder? Asking for my 68-year-old father.
Picked up the Shankhpushpi syrup vs powder prep from the section on seasonal variation. Results after 4 weeks: good.
What’s the difference between the the GABA modulation claim approach for acute vs chronic conditions?
Can combining with Jatamansi be done at home or do you need a certified practitioner? 💯